US equities
|
MU
$1,071.24
▲+2.46%
NVDA
$236.88
▼-0.99%
SNDK
$1,713.08
▲+3.17%
AMD
$643.44
▼-0.92%
INTC
$113.62
▲+1.00%
SPCX
$168.44
▼-2.02%
TSLA
$375.17
▼-1.45%
META
$722.46
▼-2.22%
MU
$1,071.24
▲+2.46%
NVDA
$236.88
▼-0.99%
SNDK
$1,713.08
▲+3.17%
AMD
$643.44
▼-0.92%
INTC
$113.62
▲+1.00%
SPCX
$168.44
▼-2.02%
TSLA
$375.17
▼-1.45%
META
$722.46
▼-2.22%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Soligenix, Inc. - Common Stock
(NQ:
SNGX
)
0.3599
-0.0001 (-0.03%)
Delayed Quote
Updated: 11:31 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Soligenix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 24, 2025
Via
Benzinga
Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
June 18, 2025
Via
Investor Brand Network
Study Finds the Overall Prevalence of Psoriasis in the US Unchanged
June 17, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
June 17, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026
June 12, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL
June 06, 2025
Via
Investor Brand Network
Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation
June 05, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (SNGX) Highlights HyBryte Progress in CTCL via New Podcast Featuring Dr. Ellen Kim
June 04, 2025
Via
Investor Brand Network
New Swallowable Pill Provides Real-Time Gut Inflammation Tracking
May 27, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics
May 23, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial
May 22, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results
May 19, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial
May 15, 2025
Via
Investor Brand Network
Study Links Higher Consumption of Ultra-Processed Foods to Heightened Psoriasis Risk
May 13, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode
May 07, 2025
Via
Investor Brand Network
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response
May 05, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response
May 05, 2025
By JE Insights, Benzinga
Via
TheNewswire.com
Bacterial Meningitis Can Now Be Rapidly Diagnosed with New Test
May 01, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer
May 01, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)
April 29, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
April 25, 2025
Via
Investor Brand Network
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
April 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
April 24, 2025
Via
TheNewswire.com
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
April 21, 2025
Via
Investor Brand Network
Topics
Death
Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis
April 21, 2025
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 11, 2025
Via
Benzinga
Study Shows the Gut is Key in Protecting the Brain After Stroke
April 08, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
April 08, 2025
Via
Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
April 03, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
March 28, 2025
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
